Grant: Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
University of Alberta
$904,236.00
Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials
FY 2020-21
Summary
The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.
Department
Program
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
429680
Name
Tyrrell D. Lorne J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Clinical
Prcname2
COVID-19 Rapid Research - Therapeutics
Projecttitle
Advancing a Potent Inhibitor of SARS-CoV-2 3CL Protease into Clinical Trials
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$904,236
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 Rapid Research Funding Opportunity - Therapeutics
Keyworddelim
Animal Disease; Antiviral Therapy; Clinical Trial; Covid-19; Feline Infectious Peritonitis; Protease Inhibitor
Abstract
The coronavirus, SARS-CoV-2, has caused COVID-19, a disease that is currently pandemic. The drug GC376 targets an enzyme in the virus that stops its replication. This drug has been used successfully to treat a fatal disease in cats known as Feline Infectious Peritonitis (FIP). FIP is caused by a coronavirus similar to the virus causing COVID-19. This study will move GC376 into phase I human trials on the path to bringing this compound to the benefit of patients with COVID-19.
Competitiondate
202005
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tyrrell, D. Lorne J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $904,236~ $0~
